Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illinois Tool Works Inc. (ITW) vs Eli Lilly And Co (LLY) Price & Performance

Illinois Tool Works Inc.Trade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Illinois Tool Works Inc. vs Eli Lilly And Co — how do they compare? Illinois Tool Works Inc. trades at $263.26 (market cap $74.38B), while Eli Lilly And Co trades at $1,166.02 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 14.3× Illinois Tool Works Inc.'s market cap, and Illinois Tool Works Inc. pays the higher dividend (2.63%). Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Eli Lilly And Co for 93 Days on average.

ITWLLY
Market Cap
$74.38B$1.06T
Volume
1,125,4772,297,239
Sector
IndustrialsHealth
52-Week High
$299.60$1.28K
52-Week Low
$241.07$799.57
Typical Hold Time
67 Days93 Days
Enterprise Value
$83.23B$1.11T
Dividend Yield
2.63%0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illinois Tool Works Inc.

ITW trades at $264.71, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 19.39% net margins and 104.65% ROE, though valuation multiples appear elevated. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of consecutive growth. Operating cash flow remains robust at $3.13B, supporting continued shareholder returns.

Outlook remains mixed with analyst consensus target of $280.14 offering 5.8% upside, but technical indicators signal near-term pressure. The company faces headwinds in automotive and foodservice segments while maintaining strong organic growth prospects. Debt levels have increased to 55.54% of assets, requiring monitoring amid rising interest rates.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.

Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ITW
75% Buy25% Sell
Avg holding period · 67 Days
LLY
69% Buy31% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Illinois Tool Works Inc.

Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.

Read more on ITW →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →